Fibroblast Growth Factor 21 as an emerging metabolic regulator: Clinical perspectives

Clinical Endocrinology

Volumn 78, Issue 4, 2013, Pages 489-496

  Woo, Y C ^a   Xu, Aimin ^a   Wang, Yu ^a   Lam, Karen S L ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; FENOFIBRATE; FIBROBLAST GROWTH FACTOR 21; GLUCOSE; GLYCEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; KLOTHO PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RECOMBINANT FIBROBLAST GROWTH FACTOR; TRANSCRIPTION FACTOR AP 1;

ADIPOCYTE; ADIPOGENESIS; ANOREXIA NERVOSA; BODY WEIGHT; BONE MASS; CHRONIC KIDNEY DISEASE; CORONARY ARTERY DISEASE; CUSHING SYNDROME; DIABETIC NEPHROPATHY; DIET RESTRICTION; DRUG EFFICACY; DRUG SAFETY; ENERGY EXPENDITURE; FATTY ACID OXIDATION; FATTY LIVER; FEEDBACK SYSTEM; FRACTURE; GENE EXPRESSION; GLUCAGON RELEASE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; GLYCEROL BLOOD LEVEL; HORMONE BLOOD LEVEL; HORMONE SYNTHESIS; HUMAN; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; KETOGENESIS; KETOGENIC DIET; LIPID METABOLISM; LIPOLYSIS; LIVER; MESENCHYMAL STEM CELL; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; UPREGULATION;

ANIMALS; FIBROBLAST GROWTH FACTORS; GLUCONEOGENESIS; HAPLORHINI; HUMANS; LIPID METABOLISM; METABOLIC DISEASES; MICE; MODELS, BIOLOGICAL;

EID: 84875124153     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12095     Document Type: Review

References (56)

1. Itoh, N., &, Ornitz, D.M., (2004) Evolution of the Fgf and Fgfr gene families. Trends in Genetics, 20, 563-569.
2. Kharitonenkov, A., (2009) FGFs and metabolism. Current Opinion in Pharmacology, 9, 805-810.
3. Nishimura, T., Nakatake, Y., Konishi, M., et al,. (2000) Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochimica et Biophysica Acta, 1492, 203-206.
4. Fon Tacer, K., Bookout, A.L., Ding, X., et al,. (2010) Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Molecular Endocrinology, 24, 2050-2064.
5. Inagaki, T., Dutchak, P., Zhao, G., et al,. (2007) Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metabolism, 5, 415-425.
6. Dutchak, P.A., Katafuchi, T., Bookout, A.L., et al,. (2012) Fibroblast growth factor-21 regulates PPARgamma activity and the antidiabetic actions of thiazolidinediones. Cell, 148, 556-567.
7. Kharitonenkov, A., Shiyanova, T.L., Koester, A., et al,. (2005) FGF-21 as a novel metabolic regulator. Journal of Clinical Investigation, 115, 1627-1635.
8. Kharitonenkov, A., Wroblewski, V.J., Koester, A., et al,. (2007) The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology, 148, 774-781.
9. Huang, X., Yu, C., Jin, C., et al,. (2006) Forced expression of hepatocyte-specific fibroblast growth factor 21 delays initiation of chemically induced hepatocarcinogenesis. Molecular Carcinogenesis, 45, 934-942.
10. Zhang, X., Yeung, D.C., Karpisek, M., et al,. (2008) Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes, 57, 1246-1253.
11. Chen, C., Cheung, B.M., Tso, A.W., et al,. (2011) High plasma level of fibroblast growth factor 21 is an Independent predictor of type 2 diabetes: a 5.4-year population-based prospective study in Chinese subjects. Diabetes Care, 34, 2113-2115.
12. Fisher, F.M., Chui, P.C., Antonellis, P.J., et al,. (2010) Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes, 59, 2781-2789.
13. Badman, M.K., Pissios, P., Kennedy, A.R., et al,. (2007) Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metabolism, 5, 426-437.
14. Lundasen, T., Hunt, M.C., Nilsson, L.M., et al,. (2007) PPARalpha is a key regulator of hepatic FGF21. Biochemical and Biophysical Research Communications, 360, 437-440.
15. Hondares, E., Iglesias, R., Giralt, A., et al,. (2011) Thermogenic activation induces FGF21 expression and release in brown adipose tissue. Journal of Biological Chemistry, 286, 12983-12990.
16. Galman, C., Lundasen, T., Kharitonenkov, A., et al,. (2008) The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metabolism, 8, 169-174.
17. Uebanso, T., Taketani, Y., Yamamoto, H., et al,. (2011) Paradoxical regulation of human FGF21 by both fasting and feeding signals: is FGF21 a nutritional adaptation factor? PLoS ONE, 6, e22976.
18. Mraz, M., Bartlova, M., Lacinova, Z., et al,. (2009) Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clinical endocrinology (Oxford), 71, 369-375.
19. Berglund, E.D., Li, C.Y., Bina, H.A., et al,. (2009) Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology, 150, 4084-4093.
20. Sarruf, D.A., Thaler, J.P., Morton, G.J., et al,. (2010) Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats. Diabetes, 59, 1817-1824.
21. Hsuchou, H., Pan, W., &, Kastin, A.J., (2007) The fasting polypeptide FGF21 can enter brain from blood. Peptides, 28, 2382-2386.
22. Kharitonenkov, A., Dunbar, J.D., Bina, H.A., et al,. (2008) FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho. Journal of Cellular Physiology, 215, 1-7.
23. Wente, W., Efanov, A.M., Brenner, M., et al,. (2006) Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes, 55, 2470-2478.
24. Moyers, J.S., Shiyanova, T.L., Mehrbod, F., et al,. (2007) Molecular determinants of FGF-21 activity-synergy and cross-talk with PPARgamma signaling. Journal of Cellular Physiology, 210, 1-6.
25. Potthoff, M.J., Inagaki, T., Satapati, S., et al,. (2009) FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. The Proceedings of the National Academy of Sciences USA, 106, 10853-10858.
26. Fisher, F.M., Estall, J.L., Adams, A.C., et al,. (2011) Integrated regulation of hepatic metabolism by fibroblast growth factor 21 (FGF21) in vivo. Endocrinology, 152, 2996-3004.
27. Badman, M.K., Koester, A., Flier, J.S., et al,. (2009) Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology, 150, 4931-4940.
28. Hotta, Y., Nakamura, H., Konishi, M., et al,. (2009) Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver. Endocrinology, 150, 4625-4633.
29. Dushay, J., Chui, P.C., Gopalakrishnan, G.S., et al,. (2010) Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology, 139, 456-463.
30. Chen, W., Hoo, R.L., Konishi, M., et al,. (2011) Growth hormone induces hepatic production of fibroblast growth factor 21 through a mechanism dependent on lipolysis in adipocytes. Journal of Biological Chemistry, 286, 34559-34566.
31. Arner, P., Pettersson, A., Mitchell, P.J., et al,. (2008) FGF21 attenuates lipolysis in human adipocytes-a possible link to improved insulin sensitivity. FEBS Letters, 582, 1725-1730.
32. Yu, H., Xia, F., Lam, K.S., et al,. (2011) Circadian rhythm of circulating fibroblast growth factor 21 is related to diurnal changes in fatty acids in humans. Clinical Chemistry, 57, 691-700.
33. Xu, J., Lloyd, D.J., Hale, C., et al,. (2009) Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes, 58, 250-259.
34. Reinehr, T., Woelfle, J., Wunsch, R., et al,. (2012) Fibroblast growth factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: a longitudinal analysis. Journal of Clinical Endocrinology and Metabolism, 97, 2143-50.
35. Mai, K., Andres, J., Biedasek, K., et al,. (2009) Free fatty acids link metabolism and regulation of the insulin-sensitizing fibroblast growth factor-21. Diabetes, 58, 1532-1538.
36. Chavez, A.O., Molina-Carrion, M., Abdul-Ghani, M.A., et al,. (2009) Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care, 32, 1542-1546.
37. Yang, M., Dong, J., Liu, H., et al,. (2011) Effects of short-term continuous subcutaneous insulin infusion on fasting plasma fibroblast growth factor-21 levels in patients with newly diagnosed type 2 diabetes mellitus. PLoS ONE, 6, e26359.
38. Lin, Z., Wu, Z., Yin, X., et al,. (2010) Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PLoS ONE, 5, e15534.
39. Li, H., Fang, Q., Gao, F., et al,. (2010) Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. Journal of Hepatology, 53, 934-940.
40. Gorar, S., Culha, C., Uc, Z.A., et al,. (2010) Serum fibroblast growth factor 21 levels in polycystic ovary syndrome. Gynecological Endocrinology, 26, 819-826.
41. Diaz-Delfin, J., Hondares, E., Iglesias, R., et al,. (2012) TNF-alpha represses beta-Klotho expression and impairs FGF21 action in adipose cells; involvement of JNK1 in the FGF21 pathway. Endocrinology, 153, 4238-4245.
42. Dostalova, I., Kavalkova, P., Haluzikova, D., et al,. (2008) Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa. Journal of Clinical Endocrinology and Metabolism, 93, 3627-3632.
43. Fazeli, P.K., Misra, M., Goldstein, M., et al,. (2010) Fibroblast growth factor-21 may mediate growth hormone resistance in anorexia nervosa. Journal of Clinical Endocrinology and Metabolism, 95, 369-374.
44. Inagaki, T., Lin, V.Y., Goetz, R., et al,. (2008) Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. Cell Metabolism, 8, 77-83.
45. Xiao, Y., Xu, A., Law, L.S., et al,. (2012) Distinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes. Journal of Clinical Endocrinology and Metabolism, 97, E54-58.
46. Johnson, C.L., Weston, J.Y., Chadi, S.A., et al,. (2009) Fibroblast growth factor 21 reduces the severity of cerulein-induced pancreatitis in mice. Gastroenterology, 137, 1795-1804.
47. Stein, S., Bachmann, A., Lossner, U., et al,. (2009) Serum levels of the adipokine FGF21 depend on renal function. Diabetes Care, 32, 126-128.
48. Lin, Z., Zhou, Z., Liu, Y., et al,. (2011) Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese. PLoS ONE, 6, e18398.
49. Jian, W.X., Peng, W.H., Jin, J., et al,. (2012) Association between serum fibroblast growth factor 21 and diabetic nephropathy. Metabolism, 61, 853-859.
50. Li, K., Li, L., Yang, M., et al,. (2009) Effects of rosiglitazone on fasting plasma fibroblast growth factor-21 levels in patients with type 2 diabetes mellitus. European Journal of Endocrinology, 161, 391-395.
51. Durovcova, V., Marek, J., Hana, V., et al,. (2010) Plasma concentrations of fibroblast growth factors 21 and 19 in patients with Cushing's syndrome. Physiological Research, 59, 415-422.
52. Lin, Z., Gong, Q., Wu, C., et al,. (2012) Dynamic change of serum FGF21 levels in response to glucose challenge in human. Journal of Clinical Endocrinology and Metabolism, 97, E1224-1228.
53. Semba, R.D., Sun, K., Egan, J.M., et al,. (2012) Relationship of serum fibroblast growth factor 21 with abnormal glucose metabolism and insulin resistance: the Baltimore Longitudinal Study of Aging. Journal of Clinical Endocrinology and Metabolism, 97, 1375-1382.
54. Coskun, T., Bina, H.A., Schneider, M.A., et al,. (2008) Fibroblast growth factor 21 corrects obesity in mice. Endocrinology, 149, 6018-6027.
55. Mu, J., Pinkstaff, J., Li, Z., et al,. (2012) FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents. Diabetes, 61, 505-512.
56. Wei, W., Dutchak, P.A., Wang, X., et al,. (2012) Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor gamma. The Proceedings of the National Academy of Sciences USA, 109, 3143-3148.